Skip to content

Patient-Derived Gastric Cancer Organoids for Predicting the Clinical Efficacy of Palliative Chemotherapy for Advanced Gastric Cancer

Patient-Derived Gastric Cancer Organoids for Predicting the Clinical Efficacy of Palliative Chemotherapy for Advanced Gastric Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000028856
Enrollment
Unknown
Registered
2020-01-05
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

Case series:Nil

Sponsors

The Seventh Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged 18-75 years; 2. ECOG score ranges from 0-1; 3. Pathologically diagnosed advanced gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) with measurable extragastric lesions (spiral CT scan =10mm according to RECIST 1.1 criterial) 4. Expected overall survival: >=3 months; 5. Other treatment-related harms have recovered. The interval for stopping nitroso or mitomycin is longer than 6 weeks; The interval with other cytotoxic drugs, radiotherapy or surgery longer than 4 weeks; The surgical wounds, if any, have completely healed; 6. Women with a negative pregnancy test (serum or urine) within 7 days before enrollment, and agree to take appropriate contraception during the trial and 8 weeks after the last drug administration. For men, they should be sterilized surgically or agreed to take appropriate contraception during the trial and 8 weeks after the last drug administration; 7. Patients volunteered to participate in the study, provide an informed consent form (ICF) with good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with clinically (i.e. active) heart disease (e.g. congestive heart failure, symptomatic coronary artery disease, arrhythmia, etc.) or myocardial infarction within the past 12 months; 2. Pregnant or lactating women; 3. Patients with other malignant tumors within 5 years; 4. Patients with a history of psychotropic substance abuse and are unable to quit or have mental disorders; 5. Patients have already been enrolled in other clinical trials in the last four weeks; 6. Investigators consider the participant is ineligible.

Design outcomes

Primary

MeasureTime frame
Disease Control Rate;

Secondary

MeasureTime frame
Completely Response Rate;Objective Response Rate;

Countries

China

Contacts

Public ContactYuan Jinqiu

The Seventh Affiliated Hospital, Sun Yat-sen University

yuanjinqiu2006@163.com+86 13169902651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026